Printer Friendly
The Free Library
14,679,626 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Zacks.com Announces That Nadine Wong Highlights: Genzyme.


CHICAGO -- Nadine Wong, editor of the BioTech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 Stock Report newsletter, profiles a biotech that is poised for a rebound rebound (rē´bownd),
n/v 1. a recovery from illness.
n 2. an outbreak of fresh reflex activity after withdrawal of a stimulus

rebound adjective
. Learn about Genzyme (Nasdaq: GENZ). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Highlights from the February 1 Featured Expert column by Nadine Wong include:

Genzyme (Nasdaq: GENZ) will report full financial results for 2006 on February 14. Pressure on its share price will likely be mitigated mit·i·gate  
v. mit·i·gat·ed, mit·i·gat·ing, mit·i·gates

v.tr.
To moderate (a quality or condition) in force or intensity; alleviate. See Synonyms at relieve.

v.intr.
To become milder.
 later this year with Renvela's approval expected October 21, 2007. Investors will focus more on the upside Upside

The potential dollar amount by which the market or a stock could rise.

Notes:
This is basically an educated guess on how high a stock could go in the near future.
See also: Bull, Downside
 of Renvela's filing which includes a chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is  label and once-daily powdered dosing, rather than near-term Renagel growth. Commercial strength elsewhere in the company's portfolio could more than offset any Renagel weakness.

Nadine Wong and her team anticipate a continued strong Myozyme launch, as well as solid Cerezyme and Fabrazyme sales performance.

Genzyme shares are poised for a rebound.

Read Nadine Wong's complete commentary on the company above by clicking: http://at.zacks.com/?id=85

About Zacks Featured Experts

Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research Zacks Investment Research

A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms.
 has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail See Internet e-mail service.  newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform Outperform

An analyst recommendation meaning a stock is expected to do slightly better than the market return.

Notes:
Exact definitions vary by brokerage, but in general this rating is better than neutral and worse than buy or strong buy.
 the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=87

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation solicitation

In criminal law, the act of asking, inducing, or directing someone to commit a crime. The person soliciting another becomes an accomplice to the crime. The term also refers to the act of obtaining bribes, as well as to the crime of a prostitute who offers sexual
 to buy or sell any security.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 2, 2007
Words:476
Previous Article:Provo Craft(R) Granted Several Honors by the Creating Keepsakes' 2006 Readers' Choice Awards.
Next Article:Courier Names Christopher Kuppig as Vice President of Business Development, Publishing.
Topics:



Related Articles
THOUSAND OAKS GIRL SKATES TO EARLY NOVICE LEAD.(Sports)(Statistical Data Included)
Zacks.com Announces That Nadine Wong Highlights: Genzyme.
Zacks.com announces that Nadine Wong highlights: Xoma.
All Star Analysts Portfolio Highlights: Electronic Arts, EMC, Genzyme and Wachovia.
All Star Analysts Portfolio Highlights: Electronic Arts, Genzyme, LaSalle Hotel Properties and PPD.
All Star Analysts Portfolio highlights: CACI Int'l, Genzyme Corporation, Kohl's Corporation and Ultra Petroleum Corporation.
Zacks.com Announces That Nadine Wong Highlights: Cubist, Celgene and Merck.
Zacks.com Announces That Nadine Wong Highlights: Theravance.
Zacks Broker Upgrades: T. Rowe Price, Norfolk Southern, Genzyme Corporation and Amgen.
Zacks Analyst Interview Highlights: MedImmune, Genzyme and Sangamo Biosciences.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles